{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T08:16:56Z","timestamp":1790669816577,"version":"4.1.0"},"reference-count":77,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gastrojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1053\/j.gastro.2013.02.041","type":"journal-article","created":{"date-parts":[[2013,3,5]],"date-time":"2013-03-05T03:50:10Z","timestamp":1362455410000},"page":"105-112.e15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":318,"title":["New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding: A Systematic Review and Meta-analysis"],"prefix":"10.1053","volume":"145","author":[{"given":"I. Lisanne","family":"Holster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera E.","family":"Valkhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernst J.","family":"Kuipers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric T.T.L.","family":"Tjwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2013.02.041_bib1","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1038\/ajg.2009.164","article-title":"Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice","volume":"104","author":"Lanas","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2013.02.041_bib2","first-page":"279","article-title":"Impact of upper and lower gastrointestinal blood loss on healthcare utilization and costs: a systematic review","volume":"14","author":"Parker","year":"2011","journal-title":"J\u00a0Med Econ"},{"key":"10.1053\/j.gastro.2013.02.041_bib3","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1136\/bmj.38947.697558.AE","article-title":"Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study","volume":"333","author":"Hallas","year":"2006","journal-title":"BMJ"},{"key":"10.1053\/j.gastro.2013.02.041_bib4","series-title":"Gastrointestinal bleeding","author":"Sung","year":"2012"},{"key":"10.1053\/j.gastro.2013.02.041_bib5","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.cgh.2011.05.020","article-title":"Low doses of acetylsalicylic acid increase risk of gastrointestinal bleeding in a meta-analysis","volume":"9","author":"Lanas","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2013.02.041_bib6","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.thromres.2011.01.016","article-title":"A\u00a0systematic review of rivaroxaban versus enoxaparin in the prevention of venous thromboembolism after hip or knee replacement","volume":"127","author":"Turun","year":"2011","journal-title":"Thromb Res"},{"key":"10.1053\/j.gastro.2013.02.041_bib7","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s00228-010-0889-z","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials","volume":"66","author":"Cao","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1053\/j.gastro.2013.02.041_bib8","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-156-10-201205150-00421","article-title":"Oral direct factor Xa inhibitors versus low-molecular-weight heparin to prevent venous thromboembolism in\u00a0patients undergoing total hip or knee replacement: a systematic review and meta-analysis","volume":"156","author":"Neumann","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.gastro.2013.02.041_bib9","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin\u00a0in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2013.02.041_bib10","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2013.02.041_bib11","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1111\/j.1538-7836.2011.04432.x","article-title":"Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents","volume":"9","author":"Levi","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1053\/j.gastro.2013.02.041_bib12","unstructured":"European Medicines Agency, an agency of the European Union. Available: www.ema.europa.eu. Accessed January 24,\u00a02013."},{"key":"10.1053\/j.gastro.2013.02.041_bib13","unstructured":"U.S. Food and Drug Administration, US Department of Health and Human Services. Available: www.fda.gov. Accessed January 24,\u00a02013."},{"key":"10.1053\/j.gastro.2013.02.041_bib14","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.ahj.2011.01.026","volume":"161","author":"Gibson","year":"2011","journal-title":"Am Heart J"},{"key":"10.1053\/j.gastro.2013.02.041_bib15","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1538-7836.2009.03678.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients","volume":"8","author":"Schulman","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1053\/j.gastro.2013.02.041_bib16","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1053\/j.gastro.2013.02.041_bib17","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1093\/eurheartj\/ehm019","article-title":"Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes","volume":"28","author":"Rao","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1053\/j.gastro.2013.02.041_bib18","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1161\/CIRCULATIONAHA.109.853119","article-title":"New anticoagulants","volume":"121","author":"Eikelboom","year":"2010","journal-title":"Circulation"},{"issue":"Suppl 1","key":"10.1053\/j.gastro.2013.02.041_bib19","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1538-7836.2011.04321.x","article-title":"Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa","volume":"9","author":"Bauer","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1053\/j.gastro.2013.02.041_bib20","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s11239-011-0559-8","article-title":"New oral anticoagulants","volume":"31","author":"Galanis","year":"2011","journal-title":"J\u00a0Thromb Thrombolysis"},{"key":"10.1053\/j.gastro.2013.02.041_bib21","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.pharmthera.2010.12.007","article-title":"The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism","volume":"130","author":"Mavrakanas","year":"2011","journal-title":"Pharmacol Ther"},{"key":"10.1053\/j.gastro.2013.02.041_bib22","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/ajh.22021","article-title":"Practical aspects of the oral new anticoagulants","volume":"86","author":"Deloughery","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1053\/j.gastro.2013.02.041_bib23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1182\/blood-2009-09-241851","article-title":"The new oral anticoagulants","volume":"115","author":"Garcia","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.gastro.2013.02.041_bib24","unstructured":"Higgins J, Green S, eds. Assessment of study quality. In: Cochrane Handbook for systematic reviews of interventions 4.2.6 [updated September 2006]. The Cochrane Library. Chichester, UK: John Wiley & Sons, Ltd,\u00a02006."},{"key":"10.1053\/j.gastro.2013.02.041_bib25","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.amjcard.2007.06.034","article-title":"Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study)","volume":"100","author":"Ezekowitz","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1053\/j.gastro.2013.02.041_bib26","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1160\/TH10-01-0066","article-title":"Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation","volume":"104","author":"Weitz","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1053\/j.gastro.2013.02.041_bib27","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1160\/TH10-07-0451","article-title":"Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation","volume":"105","author":"Chung","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1053\/j.gastro.2013.02.041_bib28","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1253\/circj.CJ-10-1183","article-title":"Safety and efficacy of the oral direct factor xa inhibitor apixaban in Japanese patients with non-valvular atrial fibrillation. The ARISTOTLE J study","volume":"75","author":"Ogawa","year":"2011","journal-title":"Circ J"},{"key":"10.1053\/j.gastro.2013.02.041_bib29","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2013.02.041_bib30","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2013.02.041_bib31","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1538-7836.2004.01100.x","article-title":"A\u00a0new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial","volume":"3","author":"Eriksson","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1053\/j.gastro.2013.02.041_bib32","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1111\/j.1538-7836.2005.01602.x","article-title":"BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study","volume":"3","author":"Turpie","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1053\/j.gastro.2013.02.041_bib33","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1538-7836.2005.01657.x","article-title":"Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement","volume":"4","author":"Eriksson","year":"2006","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1053\/j.gastro.2013.02.041_bib34","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1161\/CIRCULATIONAHA.106.642074","article-title":"A\u00a0once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement","volume":"114","author":"Eriksson","year":"2006","journal-title":"Circulation"},{"key":"10.1053\/j.gastro.2013.02.041_bib35","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.thromres.2006.12.025","article-title":"Dose-escalation study of rivaroxaban (BAY 59-7939)\u2013an oral, direct Factor Xa inhibitor\u2013for the prevention of venous thromboembolism in patients undergoing total hip replacement","volume":"120","author":"Eriksson","year":"2007","journal-title":"Thromb Res"},{"key":"10.1053\/j.gastro.2013.02.041_bib36","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1111\/j.1538-7836.2007.02748.x","article-title":"Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial","volume":"5","author":"Eriksson","year":"2007","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1053\/j.gastro.2013.02.041_bib37","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(07)61445-7","article-title":"Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial","volume":"370","author":"Eriksson","year":"2007","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2013.02.041_bib38","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1111\/j.1538-7836.2007.02764.x","article-title":"The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement","volume":"5","author":"Lassen","year":"2007","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1053\/j.gastro.2013.02.041_bib39","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1056\/NEJMoa0800374","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty","volume":"358","author":"Eriksson","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2013.02.041_bib40","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1056\/NEJMoa076016","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty","volume":"358","author":"Lassen","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2013.02.041_bib41","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)60880-6","article-title":"Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial","volume":"372","author":"Kakkar","year":"2008","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2013.02.041_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.arth.2008.01.132","article-title":"Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery","volume":"24","author":"Committee","year":"2009","journal-title":"J\u00a0Arthroplasty"},{"key":"10.1053\/j.gastro.2013.02.041_bib43","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1160\/TH08-07-0460","article-title":"A\u00a0randomized evaluation of\u00a0betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT)","volume":"101","author":"Turpie","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1053\/j.gastro.2013.02.041_bib44","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0140-6736(09)60734-0","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial","volume":"373","author":"Turpie","year":"2009","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2013.02.041_bib45","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1056\/NEJMoa0810773","article-title":"Apixaban or enoxaparin for thromboprophylaxis after knee replacement","volume":"361","author":"Lassen","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2013.02.041_bib46","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.arth.2009.08.010","article-title":"Dabigatran etexilate prevents venous thromboembolism after total knee arthroplasty in Japanese patients with a safety profile comparable to placebo","volume":"25","author":"Fuji","year":"2010","journal-title":"J\u00a0Arthroplasty"},{"key":"10.1053\/j.gastro.2013.02.041_bib47","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1111\/j.1538-7836.2010.04021.x","article-title":"A\u00a0dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty","volume":"8","author":"Fuji","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1053\/j.gastro.2013.02.041_bib48","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa1006885","article-title":"Apixaban versus enoxaparin for thromboprophylaxis after hip replacement","volume":"363","author":"Lassen","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2013.02.041_bib49","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(09)62125-5","article-title":"Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial","volume":"375","author":"Lassen","year":"2010","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2013.02.041_bib50","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1160\/TH10-02-0142","article-title":"Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study","volume":"104","author":"Raskob","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1053\/j.gastro.2013.02.041_bib51","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1160\/TH10-10-0679","article-title":"Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial","volume":"105","author":"Eriksson","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1053\/j.gastro.2013.02.041_bib52","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1110899","article-title":"Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients","volume":"365","author":"Goldhaber","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2013.02.041_bib53","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/j.1538-7836.2012.04693.x","article-title":"A\u00a0randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer","volume":"10","author":"Levine","year":"2012","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1053\/j.gastro.2013.02.041_bib54","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1161\/CIRCULATIONAHA.106.668020","article-title":"Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study","volume":"116","author":"Agnelli","year":"2007","journal-title":"Circulation"},{"key":"10.1053\/j.gastro.2013.02.041_bib55","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2008-05-160143","article-title":"A\u00a0dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study","volume":"112","author":"Buller","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.gastro.2013.02.041_bib56","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/j.1538-7836.2008.03054.x","article-title":"Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study","volume":"6","author":"Botticelli Investigators Writing Committee","year":"2008","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1053\/j.gastro.2013.02.041_bib57","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2013.02.041_bib58","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"EINSTEIN Investigators E","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2013.02.041_bib59","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"EINSTEIN-PE Investigators","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2013.02.041_bib60","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1161\/CIRCULATIONAHA.108.832139","article-title":"Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial","volume":"119","author":"APPRAISE Steering Committee and Investigators","year":"2009","journal-title":"Circulation"},{"key":"10.1053\/j.gastro.2013.02.041_bib61","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(09)60738-8","article-title":"Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial","volume":"374","author":"Mega","year":"2009","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2013.02.041_bib62","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with antiplatelet therapy after acute coronary syndrome","volume":"365","author":"Alexander","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2013.02.041_bib63","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2013.02.041_bib64","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1093\/eurheartj\/ehr113","article-title":"Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial","volume":"32","author":"Oldgren","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1053\/j.gastro.2013.02.041_bib65","doi-asserted-by":"crossref","first-page":"e3675","DOI":"10.1136\/bmj.e3675","article-title":"Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons","volume":"344","author":"Gomez-Outes","year":"2012","journal-title":"BMJ"},{"key":"10.1053\/j.gastro.2013.02.041_bib66","article-title":"Novel oral anticoagulants versus warfarin in non-valvular atrial fibrillation: a meta-analysis of 50,578 patients","author":"Capodanno","year":"2012","journal-title":"Int J Cardiol"},{"key":"10.1053\/j.gastro.2013.02.041_bib67","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.amjcard.2012.03.049","article-title":"Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation","volume":"110","author":"Miller","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1053\/j.gastro.2013.02.041_bib68","doi-asserted-by":"crossref","first-page":"4471","DOI":"10.1182\/blood-2007-11-123711","article-title":"Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based","volume":"111","author":"Levi","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.gastro.2013.02.041_bib69","doi-asserted-by":"crossref","first-page":"101","DOI":"10.7326\/0003-4819-152-2-201001190-00009","article-title":"International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding","volume":"152","author":"Barkun","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.gastro.2013.02.041_bib70","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1572-0241.2006.01062.x","article-title":"Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants","volume":"102","author":"Lanas","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2013.02.041_bib71","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1161\/01.CIR.0000145172.55640.93","article-title":"Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin","volume":"110","author":"Gage","year":"2004","journal-title":"Circulation"},{"key":"10.1053\/j.gastro.2013.02.041_bib72","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","article-title":"Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation","volume":"285","author":"Gage","year":"2001","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2013.02.041_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2009.02.005","article-title":"Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran","volume":"157","author":"Ezekowitz","year":"2009","journal-title":"Am Heart J"},{"key":"10.1053\/j.gastro.2013.02.041_bib74","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ahj.2009.08.026","article-title":"Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment","volume":"159","author":"Eikelboom","year":"2010","journal-title":"Am Heart J"},{"key":"10.1053\/j.gastro.2013.02.041_bib75","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ahj.2009.11.025","article-title":"Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study","volume":"159","author":"ROCKET AF Study Investigators","year":"2010","journal-title":"Am Heart J"},{"key":"10.1053\/j.gastro.2013.02.041_bib76","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ahj.2009.07.035","article-title":"Apixaban for reduction in\u00a0stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale","volume":"159","author":"Lopes","year":"2010","journal-title":"Am Heart J"},{"key":"10.1053\/j.gastro.2013.02.041_bib77","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/s-0038-1651587","article-title":"A method to determine the optimal intensity of oral anticoagulant therapy","volume":"69","author":"Rosendaal","year":"1993","journal-title":"Thromb Haemost"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508513002904?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508513002904?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T15:04:10Z","timestamp":1758035050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508513002904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":77,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S0016508513002904"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2013.02.041","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717995230.793475240","asserted-by":"object"}]},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding: A Systematic Review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2013.02.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 AGA Institute. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}